Compare NGL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | SDGR |
|---|---|---|
| Founded | 1940 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2011 | 2020 |
| Metric | NGL | SDGR |
|---|---|---|
| Price | $14.30 | $27.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $33.57 |
| AVG Volume (30 Days) | 167.7K | ★ 1.6M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,156,159,000.00 | $255,869,000.00 |
| Revenue This Year | $5.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $8.62 | $10.95 |
| 52 Week High | $19.06 | $34.00 |
| Indicator | NGL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 49.54 |
| Support Level | $12.69 | $27.69 |
| Resistance Level | $16.57 | $32.15 |
| Average True Range (ATR) | 0.68 | 2.53 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 2.95 | 25.67 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.